Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

Rosuvastatin (2R)-Lactone

● Auf Lager

Katalog-Nr.::	VE0026637
CAS-Nr.::	N/A
Summenformel::	C22H26FN3O5S
Molare Masse::	463.52 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu

Parent drug

Rosuvastatin

IUPAC-Name

N-[4-(4-fluorophenyl)-5-[(E)-2-[(2R)-4-hydroxy-6-oxooxan-2-yl]ethenyl]-6-propan-2-ylpyrimidin-2-yl]-N-methylmethanesulfonamide

SMILES

[H]/C(C1=C(C2=CC=C(F)C=C2)N=C(N(S(=O)(C)=O)C)N=C1C(C)C)=C([C@H]3CC(O)CC(O3)=O)/[H]

InChI

InChI=1S/C22H26FN3O5S/c1-13(2)20-18(10-9-17-11-16(27)12-19(28)31-17)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)32(4,29)30/h5-10,13,16-17,27H,11-12H2,1-4H3/b10-9+/t16?,17-/m0/s1

Beschreibung

Rosuvastatin (2R)-Lactone is a cyclic lactone impurity formed via intramolecular esterification of rosuvastatin's hydroxy acid moiety under acidic or thermal conditions. As a less polar, more lipophilic degradation product it can alter assay accuracy, dissolution behavior and stability profiles, so it is routinely monitored during synthesis, formulation and stability testing. Identification and quantification are performed by reversed-phase HPLC with UV detection and confirmed by LC-MS and NMR for structural elucidation. Process and formulation controls such as pH management, solvent selection and robust impurity profiling are implemented to limit formation and ensure compliance with regulatory and pharmacopeial expectations.